Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment

PPARγ Co-Activator-1α (PGC-1α) Reduces Amyloid-β Generation Through a PPARγ-Dependent Mechanism

(2018) Loukia Katsouri et al.   JOURNAL OF ALZHEIMERS DISEASE

Fyn, a Potential Target for Alzheimer's Disease

(2018) Kai Yang et al.   JOURNAL OF ALZHEIMERS DISEASE

The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers

(2018) David Wallon et al.   JOURNAL OF ALZHEIMERS DISEASE

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

Can Nutrients Prevent or Delay Onset of Alzheimer's Disease?

(2017) Patrick J.G.H. Kamphuis et al.   JOURNAL OF ALZHEIMERS DISEASE

Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer’s Disease

(2015) Anne Robert et al.   ACCOUNTS OF CHEMICAL RESEARCH

Epidemiologia da Demência e da Doença de Alzheimer em Portugal: Estimativas da Prevalência e dos Encargos Financeiros com a Medicação

(2015) Isabel Santana et al.   Acta Medica Portuguesa

2015 Alzheimer's disease facts and figures

(2015)   Alzheimers & Dementia

Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice

(2015) Qiong Zhou et al.   ANNALS OF NEUROLOGY

Emerging drug targets for Aβand tau in Alzheimer's disease: a systematic review

(2015) Sophie West et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

(2015) Robert Baranello et al.   Current Alzheimer Research

Antibody-targeted drugs and drug resistance—Challenges and solutions

(2015) LeeRon Shefet-Carasso et al.   DRUG RESISTANCE UPDATES

Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect

(2015) Marina Miguel-Álvarez et al.   DRUGS & AGING

Alzheimer-associated A  oligomers impact the central nervous system to induce peripheral metabolic deregulation

(2015) J. R. Clarke et al.   EMBO Molecular Medicine

Masitinib for the treatment of mild to moderate Alzheimer’s disease

(2015) Jaume Folch et al.   Expert Review of Neurotherapeutics

Stabilization of Nontoxic A -Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease

(2015) T. M. Ryan et al.   JOURNAL OF NEUROSCIENCE

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A  Pharmacodynamic Responses in Mice, Dogs, and Humans

(2015) P. C. May et al.   JOURNAL OF NEUROSCIENCE

Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline

(2015) Sarah Gourmaud et al.   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease

(2015) Kimiko Konishi et al.   Neurodegenerative Diseases

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Invited review: Drug development for tauopathies

(2015) Fiona Grüninger   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Neuronal stress signaling and eIF2α phosphorylation as molecular links between Alzheimer's disease and diabetes

(2015) Mychael V. Lourenco et al.   PROGRESS IN NEUROBIOLOGY

Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death

(2015) Daniela Rossi   PROGRESS IN NEUROBIOLOGY

Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease

(2015) Diego Gomez-Nicola et al.   Alzheimers Research & Therapy

Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease

(2015) Fernanda G. De Felice et al.   Frontiers in Aging Neuroscience

Masitinib for the treatment of mild to moderate Alzheimer’s disease

(2015) Jaume Folch et al.   Expert Review of Neurotherapeutics

Nerve Growth Factor Gene Therapy

(2015) Mark H. Tuszynski et al.   JAMA Neurology

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

(2015) Katja Hochgräfe et al.   Acta Neuropathologica Communications

Design, Synthesis, and Evaluation of Multitarget-Directed Selenium-Containing Clioquinol Derivatives for the Treatment of Alzheimer’s Disease

(2014) Zhiren Wang et al.   ACS Chemical Neuroscience

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

(2014) Sergio T. Ferreira et al.   Alzheimers & Dementia

The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease

(2014) David A. Drachman   Alzheimers & Dementia

Emerging Therapeutics for Alzheimer's Disease

(2014) Karen Chiang et al.   Annual Review of Pharmacology and Toxicology

Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?

(2014) Ada Tata et al.   CNS & Neurological Disorders-Drug Targets

CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro

(2014) Nicole Ronsisvalle et al.   Current Alzheimer Research

Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease

(2014) F. G. De Felice et al.   DIABETES

Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status

(2014) Maria J. Ramirez et al.   DRUGS

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?

(2014) Francesco Panza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Investigational drugs in Alzheimer's disease: current progress

(2014) Camryn Berk et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

(2014) Khalid Iqbal et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Combined Treatment with a BACE Inhibitor and Anti-A  Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice

(2014) H. Jacobsen et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

(2014) David Wilkinson et al.   LANCET NEUROLOGY

Targeting the β secretase BACE1 for Alzheimer's disease therapy

(2014) Riqiang Yan et al.   LANCET NEUROLOGY

Dietary and lifestyle guidelines for the prevention of Alzheimer's disease

(2014) Neal D. Barnard et al.   NEUROBIOLOGY OF AGING

Nutrition and the brain: what advice should we give?

(2014) James K. Cooper   NEUROBIOLOGY OF AGING

Clinical trial of an inhibitor of RAGE-A  interactions in Alzheimer disease

(2014) D. Galasko et al.   NEUROLOGY

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

(2014) Tara L. Spires-Jones et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights

(2014) Dharmini C. Mehta et al.   PHARMACEUTICAL RESEARCH

Clioquinol promotes the degradation of metal-dependent amyloid-  (A ) oligomers to restore endocytosis and ameliorate A  toxicity

(2014) K. E. S. Matlack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

(2014) Haakon B Nygaard et al.   Alzheimers Research & Therapy

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease

(2014) Kelly Willemijn Menting et al.   Frontiers in Aging Neuroscience

Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

(2014) Wei Qiao Qiu et al.   Frontiers in Aging Neuroscience

Alzheimer disease immunotherapeutics: Then and now

(2014) Harashish Jindal et al.   Human Vaccines & Immunotherapeutics

Physiological and pathological phosphorylation of tau by Cdk5

(2014) Taeko Kimura et al.   Frontiers in Molecular Neuroscience

On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis

(2013) Michael A. Castello et al.   AGEING RESEARCH REVIEWS

Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex

(2013) T.L. Wallace et al.   BIOCHEMICAL PHARMACOLOGY

The dendritic hypothesis for Alzheimer's disease pathophysiology

(2013) J. Nicholas Cochran et al.   BRAIN RESEARCH BULLETIN

TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys

(2013) Mychael V. Lourenco et al.   Cell Metabolism

Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study

(2013) Masaaki Hokama et al.   CEREBRAL CORTEX

Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2013) Jessica Freiherr et al.   CNS DRUGS

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

(2013) Joel Ross et al.   Current Alzheimer Research

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?

(2013) Haythum O Tayeb et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Connecting Type 2 diabetes to Alzheimer’s disease

(2013) Fernanda G De Felice   Expert Review of Neurotherapeutics

Alzheimer’s disease and insulin resistance: translating basic science into clinical applications

(2013) Fernanda G. De Felice   JOURNAL OF CLINICAL INVESTIGATION

MER5101, a Novel A 1-15:DT Conjugate Vaccine, Generates a Robust Anti-A  Antibody Response and Attenuates A  Pathology and Cognitive Deficits in APPswe/PS1 E9 Transgenic Mice

(2013) B. Liu et al.   JOURNAL OF NEUROSCIENCE

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition

(2013) Brittany L. Adler et al.   NEUROBIOLOGY OF AGING

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nutritional approaches in the risk reduction and management of Alzheimer's disease

(2013) Weiqian Mi et al.   NUTRITION

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease

(2013) Robert Nisticò et al.   Drug Design Development and Therapy

Neurotoxicity of Amyloid  -Protein: Synaptic and Network Dysfunction

(2013) L. Mucke et al.   Cold Spring Harbor Perspectives in Medicine

Trafficking and Proteolytic Processing of APP

(2013) C. Haass et al.   Cold Spring Harbor Perspectives in Medicine

Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease

(2013) Bárbara Cardoso et al.   Clinical Interventions in Aging

Are Tau Aggregates Toxic or Protective in Tauopathies?

(2013) Catherine M. Cowan et al.   Frontiers in Neurology

Rational heterodoxy: Cholesterol reformation of the amyloid doctrine

(2012) Michael A. Castello et al.   AGEING RESEARCH REVIEWS

Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects

(2012) Bruno P. Imbimbo et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Deregulated Cdk5 Activity Is Involved in Inducing Alzheimer’s Disease

(2012) Varsha Shukla et al.   ARCHIVES OF MEDICAL RESEARCH

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Alzheimer Mechanisms and Therapeutic Strategies

(2012) Yadong Huang et al.   CELL

Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men

(2012) Gary Tong et al.   CLINICAL DRUG INVESTIGATION

A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects

(2012) Randy Dockens et al.   CLINICAL PHARMACOKINETICS

Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

(2012) Orly Weinreb et al.   CURRENT DRUG TARGETS

Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols

(2012) Jason Pitt et al.   FASEB JOURNAL

Is RAGE still a therapeutic target for Alzheimer’s disease?

(2012) Richard J Deane   Future Medicinal Chemistry

The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice

(2012) B. Zhang et al.   JOURNAL OF NEUROSCIENCE

JNK3 Perpetuates Metabolic Stress Induced by Aβ Peptides

(2012) Sung Ok Yoon et al.   NEURON

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes

(2011) Bruno P. Imbimbo et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel

(2011) Or A. Shemesh et al.   NEUROBIOLOGY OF DISEASE

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Association of Alzheimer disease pathology with abnormal lipid metabolism: The Hisayama Study

(2011) T. Matsuzaki et al.   NEUROLOGY

GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons

(2011) Aurelio Vazquez de la Torre et al.   PHARMACOLOGICAL RESEARCH

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease

(2011) Robert Vassar et al.   Alzheimers Research & Therapy

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

(2011) François Piette et al.   Alzheimers Research & Therapy

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) Michael Gold et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer’s disease model

(2010) Niall M. Corcoran et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Measurement of anti-beta amyloid antibodies in human blood

(2010) Paul Szabo et al.   JOURNAL OF NEUROIMMUNOLOGY

Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation

(2010) John M. Ringman et al.   NEUROSCIENCE LETTERS

Effects of Long-Term Pioglitazone Treatment on Peripheral and Central Markers of Aging

(2010) Eric M. Blalock et al.   PLoS One

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

(2010) J. van Eersel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identifying and validating biomarkers for Alzheimer's disease

(2010) Christian Humpel   TRENDS IN BIOTECHNOLOGY

PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia

(2009) Weiping Qin et al.   ARCHIVES OF NEUROLOGY

Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study

(2009) S. Gauthier et al.   Journal of Nutrition Health & Aging

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

(2009) Tomohiko Sato et al.   NEUROBIOLOGY OF AGING

Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease

(2008) Natalia Nalivaeva et al.   Current Alzheimer Research

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease

(2008) R. Deane et al.   CURRENT PHARMACEUTICAL DESIGN

Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

(2008) K A Bates et al.   MOLECULAR PSYCHIATRY

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING